fbpx

Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Multiple Myeloma Patients are ALL “Toxicity-Vulnerable”

Share Button

Are you a “Toxicity-Vulnerable” Multiple Myeloma Patient? “This prospective multicenter study demonstrated that chemotherapy toxicity is common in older adults, with 53% experiencing at least one grade 3 to 5 toxicity.”

It isn’t just old people who are “vulnerable to chemotherapy toxicity.Everyone suffers collateral damage when they undergo chemotherapy. I’m not just talking about the short-term side effects that people associate with chemotherapy such as hair loss and nausea. I’m talking about heart, brain and nerve damage. Common side effects that the majority of multiple myeloma patients suffer from.

I know. I was first diagnosed with multiple myeloma when I was 36 back in 1994. I was strong and otherwise healthy. Yet the chemotherapy regimens I underwent during ’95-’96 left me with short, long-term and late stage side effects. Some of these side effects healed. Some didn’t. Some side effects got worse over time.

Practically speaking, MMers must think long-term. Studies show that achieving complete or very-good partial remission is not required for a long overall survival. Meaning your induction therapy is probably going to be the first chemo regimen of several over the next decade or two.

There is a solution. Evidence-based Integrative therapies to enhance the efficacy of your chemo. Evidence-based, anti-MM nutrition, supplementation and lifestyle therapies.

The article linked and excerpted below talks about a chemo regimen for newly diagnosed MMers called VCD-Lite that is effective but should be used only for older folks who are too frail to withstand higher doses of chemotherapy.

Multiple Myeloma at a glance. Click the image below-

Multiple Myeloma Mind Map

The solution is not rocket science. I’m not talking about some sort of “ancient Chinese secret.” The induction chemotherapy “VCD-Lite” discussed below combined with the Multiple Myeloma Cancer Coaching Program will mean effective MM management with a LOT LESS toxicity.

Have you been diagnosed with MM? What symptoms are you experiencing? Scroll down the page, post a question or a comment and I will reply to you ASAP. Click the link on the right side of the page to watch the free webinar about the MM CC Program.

Thank you,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:


Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study

“Older adults are vulnerable to chemotherapy toxicity; however, there are limited data to identify those at risk. The goals of this study are to identify risk factors for chemotherapy toxicity in older adults and develop a risk stratification schema for chemotherapy toxicity...

Chemotherapy Toxicity

At least one grade 3 to 5 toxicity occurred in 53% of patients (39% grade 3, 12% grade 4, and 2% grade 5 [percentages reflect the worst grade of toxicity experienced]; Table 3). Grade 3 to 5 hematologic and nonhematologic toxicity occurred in 26% and 43%, respectively. The most common grade 3 to 5 hematologic toxicities were neutropenia (11%), leucopenia (10%), and anemia (10%). The most common grade 3 to 5 nonhematologic toxicities were fatigue (16%), infection (10%), and dehydration (9%). Thirty-one percent of patients required a dose reduction during therapy, 31% had a dose delay, and 23% were hospitalized during treatment…

DISCUSSION

This prospective multicenter study demonstrated that chemotherapy toxicity is common in older adults, with 53% experiencing at least one grade 3 to 5 toxicity. Among these, 2% experienced a treatment-related mortality. A predictive model was developed to identify those patients at greatest risk, including factors obtained in everyday practice (patient age, number of chemotherapy drugs, dosing, and laboratory values) and factors not typically used in everyday oncology practice (geriatric assessment variables). This model had a greater ability to discriminate risk of chemotherapy toxicity than the KPS, which is commonly used in oncology practice.

Older adults are at increased risk for chemotherapy toxicity; however, oncologists are left with little guidance when it comes to identifying risk factors other than chronologic age.

It is generally recognized that chronologic age does not equate to physiologic age. Geriatricians perform a geriatric assessment to identify clinical predictors of morbidity and mortality; however, this assessment has not been routinely incorporated into oncology care because of the time and resource requirements. Furthermore, there is a lack of guidelines regarding how to interpret the findings in the context of oncology care…”

‘VCD-Lite’ Viable Option for Older, Toxicity-Vulnerable Myeloma Patients

“Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma…

“With the high and increasing proportion of patients with multiple myeloma being very old and/or otherwise vulnerable to chemotherapy toxicity, it is increasingly important to determine the best regimens for treating these patients, yet existing clinical studies largely miss that mark by focusing on younger, fitter patients,”

“The best regimens maximize the likelihood of multiple myeloma control, ie, efficacy, while minimizing risk of severe toxicity…

Meanwhile, regarding current clinical practice we recognize recent studies that have shown that induction regimens that incorporate both proteasome inhibitors and immunomodulatory agents are likely the emerging standard of care for newly diagnosed myeloma,” the researchers wrote. “As a result, off protocol we frequently employ the dose-reduced lenalidomide, bortezomib, dexamethasone (‘RVD-lite’) for patients willing to come for once weekly bortezomib.””

 

 

Leave a Comment:

19 comments
What Kind of Pain Does Multiple Myeloma Cause? - PeopleBeatingCancer says last week

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
Colin Bishop says 8 months ago

Dear David, I am having a period of no treatment.
I am eighty and I was diagnosed in April 2016. I was also diagnosed with bowel cancer later that year. The bowel cancer was tiny and was treated with radiation and surgery before the end of that year. The bowel cancer has not been a problem since then.
I started MM treatment in January of 2017. In my memory it was thalidomide, but I think there were other treatments as well as I remember being in day ward and liquids running into me, also injections into the abdomen.
I soon felt strange sensations in my feet and before long thalidomide was reduced and then abandoned.
The haematologist told me that I wasn’t a candidate for stem cell therapy after all and for about nine months I had no treatment.
May I say here that the only MM symptoms I have had have been difficult nose bleeds and frequent pneumonia; however, these symptoms if that is what they were have not persisted and outwardly I appear perfectly healthy.
I think I began on Lenalidomide early in 2018 because the haemotologists thought my paraproteins (that is the surrogate they use here) had reached an unacceptable level. The treatment was Lenalidomide and dexamethosone. After year the dexamethosone was dropped.
The paraprotein levels came down, became stationary, then started to rise. A new haematologist took over. He doubled the Lenalidomide dose, added dexamethosone and cylophosamide. In a few months this regime got the paraproteins down to two.
At this level I asked for a holiday from treatment as a lot of my life was being spent in the toilet and I had to prepare by not eating for any appointment.
After three weeks my toilet activity is more normal, i.e. once or twice a day,
After the bowel cancer operation I had an iliostomy which the surgical fiends left in place for nineteen months, so my bowel had forgotten what it’s job was. This meant handball between surgery and hamotlogy as to who was responsible for the diarrhoea and loss of bowel control.
Anyway, there’s the whole boring story. I look well, I feel well. I will have a blood test Tuesday week and a hospital review the week after that.

Reply
Kyprolis Inc. Survival, Dec. Quality of Life- Multiple Myeloma - PeopleBeatingCancer says 9 months ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
Reid Lolly says last year

Im 71 years old and was diagnosed November 13 2020 in stage one with IgA multiple myeloma. I was walking through a stand of dead trees and heard a limb crack above. I snapped my head back and felt a crack in my neck. The mri showed a crack in the C2 and a small lesion. They gave me the news at the Hospital in Tupelo MS. The next day I was on my way to Moffit in Tampa FL. I live in Naples FL only a hundred miles away.
I got the kyphoplasty a couple of weeks later. My team of Doctors scheduled my treatment of RVD- lite to start January 4 2020. I became very sick by that day with my calcium level being 15.8. They admitted in the hospital that day for a week until my numbers came down before starting treatment.

Five cycles of treatment and an ASCT in June. Did very well through the transplant very few side effects. My m-spike started out after the transplant at .03 and began to slowly climb each week to .63. Did a bone biopsy and found seven percent still.
I started back on RVD-lite plus Darzalex. Every week for eight weeks, every other week for 12 weeks, then once a month.

Sorry for the long story but I wanted you to know my story to now. My question is can you survive very long with your bone marrow showing 7-10 percent? I’m very concerned about my kidneys they have me on 800 mg of Acyclovir daily for 6 months. Even my kidney Doctor is concerned of the length of time for that high dose.
My numbers are all very good for my kidneys and my liver and my heart is very strong with clear arteries.
I am very interested in your program and have already bought in. Am slowly working my way through.
God bless everyone with this dreaded desease and I hope everyone is able to live a long quality life

Reply
    David Emerson says last year

    Hi Reed- I replied to your question via your email address- David Emerson

    Reply
Relapsed Refractory Multiple Myeloma & The Elderly Patient - PeopleBeatingCancer says a couple of years ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
Long-Term Multiple Myeloma Survival- The Keys To Success- PeopleBeatingCancer says a couple of years ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
Multiple Myeloma Remission- QOL or PFS? - PeopleBeatingCancer says a couple of years ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
Myeloma Diagnosis- Stage 1- Non-toxic Therapies Only? - PeopleBeatingCancer says a couple of years ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
Myeloma Coaching- Can I Manage my MM w/ Non-toxic Therapies Only? - PeopleBeatingCancer says 3 years ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
"Transplants are exhausting, and they are costly." Is There A Better Way? - PeopleBeatingCancer says 3 years ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
Remission for Myeloma- QOL or PFS? - PeopleBeatingCancer says 3 years ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
Mind-Body Give / Receive Myeloma Therapy - PeopleBeatingCancer says 3 years ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
Myeloma "Miracle Cancer Cures" Pros and Cons- PeopleBeatingCancer says 3 years ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
Longer PFS w/ Increased Side Effects w/ Inc. Kyprolis Dose? - PeopleBeatingCancer says 3 years ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” Carf. Induced Heart Damage in Multiple Myeloma Multiple Myeloma- Newly Diagnosed Without Intent to ASCT […]

Reply
Multiple Myeloma- Newly Diagnosed Without Intent to ASCT - PeopleBeatingCancer says 4 years ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
Gradual Response Better then Fast Response in Myeloma Therapy? - PeopleBeatingCancer says 4 years ago

[…] Multiple Myeloma Patients are ALL “Toxicity-Vulnerable” […]

Reply
Jim says 4 years ago

What doses are used with RVD lite? My M-spike has climbed back up to 1.6 and I am scheduled to go back on VRd using 25mg Revlimid,40mg Dex once per week and I am not sure the Valcade dose tomorrow. I am 70 and did 8 courses of VRd from 11/16 to 4/17. I have been off all chemo since then.

Reply
    David Emerson says 4 years ago

    Hi Jim,

    To answers to your question “What doses are used with RVD lite?” Once a chemotherapy regimen has been approved by the FDA, it is up to the oncologist to determine the dosing schedule. Yes, there is an equation based on body weight but your oncologist decides. The real issue is what, if any side effects are you experiencing? Your m-spike is pretty low so you don’t need to undergo aggressive chemotherapy.

    The other issue for you to consider is how did you react to your original 8 courses of VRd? If you tolerated that induction therapy well then again, there is less for your oncologist to worry about it.

    I would be remiss if I didn’t mention evidence-based non-conventional integrative therapies. For example, curcumin has been shown to enhance the efficacy of Velcade (bortezomib).

    Integrative therapies such as curcumin have been shown to slow multidrug resistance. Let me know if you have any other questions.

    David Emerson

    Reply
Add Your Reply